Abiopharma

News list

Chan Mitchell 🟢 acquired 113.4K shares (1 derivative) of REGENXBIO Inc. (RGNX) at $14.18 Transaction Date: Jan 06, 2026 | Filing ID: 000002

Full text

News bot Jan. 8, 2026, 9:36 p.m.
🔍 Chan Mitchell (Executive)

Company: REGENXBIO Inc. (RGNX)

Report Date: 2026-01-06
Transaction Summary:
- Total transactions: 2
- Derivative instruments: 1
- Holdings reported: 0
- Total shares acquired: 113,399
Detailed Transactions and Holdings:
- Acquired 73,749 shares of Common Stock (Direct)
  Date: 2026-01-06 | Code: A | equity_swap_involved: false | shares_owned_after: 127,717.00 | transaction_form_type: 4 | Footnotes: F1
- Acquired 39,650 shares of Stock Options (Right to buy) at $14.18 per share (Derivative)
  Date: 2026-01-06 | Code: A | Expires: 2036-01-06 | equity_swap_involved: false | shares_owned_after: 39,650.00 | transaction_form_type: 4 | Footnotes: F2
Footnotes:
- F1: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 25% of the shares subject to this RSU will vest on each of January 6, 2027, January 6, 2028, January 6, 2029 and January 6, 2030 while the recipient provides continuous service to the Issuer.
- F2: 25% of the shares subject to this option shall vest after 12 months of continuous service with the Issuer. The balance will vest in equal monthly installments over the 36 months following January 6, 2027 while the optionee provides continuous service to the Issuer.